广泛期小细胞肺癌一线化免后胸部放疗联合度伐利尤单抗维持的II期研究
SAKK 15/19是一项多中心单臂II期研究,评估广泛期小细胞肺癌患者在接受卡铂+依托泊苷+度伐利尤单抗一线治疗后行巩固性胸部放疗的疗效。中位无进展生存期6.4个月,中位总生存期15.0个月,未观察到额外的严重放疗相关毒性。
要点
- 巩固性胸部放疗联合度伐利尤单抗维持未达到12个月无进展率≥25%的主要终点。
- 中位无进展生存期6.4个月,中位总生存期15.0个月。
- 3-4级治疗相关不良事件发生率23.9%,以中性粒细胞减少为主,无严重放疗相关毒性。
核心结论
- 在广泛期小细胞肺癌一线化疗联合度伐利尤单抗后行巩固性胸部放疗,未达到预期的12个月无进展率主要终点。
- 未观察到胸部放疗带来的额外严重毒性。
研究设计与样本
- SAKK 15/19为全国性、多中心、单臂、前瞻性II期研究。
- 患者接受卡铂AUC5(第1天)、依托泊苷100 mg/m²(第1-3天)和度伐利尤单抗1500 mg(第1天)共4周期,无进展者随后接受度伐利尤单抗每4周维持治疗最长2年。
- 胸部放疗为39 Gy分13次、2.5周内完成,在化免治疗后5周内进行;允许预防性颅脑照射。
- 主要终点为12个月无进展率,目标为≥25%(H1)对比≤12.5%。
主要发现
- 37%的患者ECOG评分为0,30%有无症状脑转移。
- 中位随访29个月时,12个月无进展率为15.6%(95%CI 7-27.5)。
- 中位无进展生存期为6.4个月(95%CI 4.8-7.2),中位总生存期为15.0个月(95%CI 10.2-22.0)。
- 3-4级治疗相关不良事件发生于23.9%的患者,主要为中性粒细胞减少(23.9%)和血小板减少(8.4%)。
- 1例患者(2%)发生5级脓毒症;未观察到严重放疗相关毒性。
关键数值与推荐
- 主要终点12个月无进展率为15.6%(95%CI 7-27.5),未达到≥25%的预设目标。
- 胸部放疗剂量为39 Gy分13次,2.5周内完成,化免治疗后5周内开始。
- 度伐利尤单抗维持剂量为1500 mg每4周,最长2年。
临床怎么用
- 该方案在广泛期小细胞肺癌中未达到主要疗效终点,暂不支持作为标准巩固治疗常规应用。
- 胸部放疗未增加严重毒性,安全性可控。
- 需等待正在进行的III期试验(如RAPTOR)进一步明确胸部放疗在此 setting 中的作用。
局限性
- 主要终点未达到,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Small cell lung cancer (SCLC) is an aggressive tumour type accounting for 10-15 % of lung cancers. The role of thoracic radiotherapy (TRT) in extensive stage SCLC (ES_SCLC) in the era of checkpoint inhibitors (CPIs) is undefined. METHODS: SAKK 15-19 is a national, multicenter, single-arm prospective phase II study evaluating consolidative TRT after standard first-line chemotherapy plus durvalumab in ES-SCLC. Patients (pts) with confirmed ES-SCLC and ECOG ≤ 1 received carboplatin AUC5 (day 1), etoposide 100 mg/m² (days 1-3) and durvalumab 1500 mg (day 1) for 4 cycles, followed by maintenance durvalumab every 4 weeks for up to 2 years in pts without progression. TRT (39 Gy in 13 fractions over 2.5 weeks) was delivered within 5 weeks after chemoimmunotherapy. Prophylactic cranial irradiation was permitted. The primary endpoint was 12-month progression-free rate (PFR); secondary endpoints included progression-free survival (PFS), response rate and overall survival (OS). The study aimed at a 12-month PFR ≥ 25 % (H1) vs. ≤ 12.5 %. RESULTS: Forty-six pts were enrolled; 37 % had ECOG 0, 30 % had asymptomatic brain metastases. At 29-month follow-up, the 12-month PFR was 15.6 (95 % CI 7-27.5), median PFS 6.4 months (95 % CI 4.8-7.2) and median OS 15.0 months (95 % CI 10.2-22.0). Grade 3-4 treatment-related adverse events (TRAEs) occurred in 23.9 % of pts, mainly neutropenia (23.9 %) and thrombocytopenia (8.4 %). One pt (2 %) had grade 5 sepsis; no severe TRT-related toxicities were observed. CONCLUSIONS: Adding consolidative TRT after chemotherapy plus durvalumab in ES-SCLC didn't meet the primary endpoint of the expected 12-month PFR. No additional severe toxicities from TRT were observed. Ongoing larger Phase III trials, including RAPTOR (LNRG LU007), will further define TRT's role in this setting.
引用
- Addeo A, Dietrich D, Mach N, et al. Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19). Eur J Cancer. 2025. PMID: 41344066. doi:10.1016/j.ejca.2025.116138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。